ArticleBMC oral health2026
Activation of Wnt/β-catenin signaling in histologically non-dysplastic non-homogeneous oral leukoplakia.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeOral potentially malignant disorders (OPMD) are lesions that precede oral cancer in approximately 15-40% of cases. Leukoplakia is the most frequent type of OPMD, and is clinically classified as homogeneous oral leukoplakia (HOL) or non-homogeneous oral leukoplakia (NHOL) according to lesion color, surface characteristics, and clinical uniformity. Compared to HOL, NHOL is less frequent and is associated with higher malignant transformation rates. This difference is even more evident in lesions histopathologically diagnosed as non-dysplastic, including hyperplasia and hyperkeratosis. To the date, there is no signaling pathway that may explain this. We and others have shown that the Wnt/β-catenin pathway, characterized by stabilization and nuclear translocation of β-catenin for expression proliferation and survival genes, is key for dysplastic HOL carcinogenesis. The role of the Wnt/β-catenin pathway in dysplastic and non-dysplastic NHOL remains unknown.
methodsFifty-seven retrospective biopsies from patients with NHOL and HOL were used. Histological diagnosis was performed with Hematoxylin & Eosin (H&E) staining, while Wnt/β-catenin activity of signaling pathway was evaluated by immunohistochemical expression of the ligand Wnt3a and nuclear localization of β-catenin, as well as downstream proliferation markers Cyclin D1 and Ki-67.
resultsNHOL lesions histologically diagnosed as hyperplasia/hyperkeratosis (non-dysplastic), displayed significantly higher expression of Wnt3a and nuclear β-catenin, as well as Cyclin D1 and Ki-67, compared to non-dysplastic HOL and healthy oral mucosa. No significant differences were observed when comparing Wnt3a, nuclear β-catenin, Cyclin D1 and Ki-67 expression between non-dysplastic HOL and healthy oral mucosa. Both dysplastic NHOL and HOL samples, compared to healthy oral mucosa, presented significant upregulation of Wnt3a, nuclear β-catenin, Cyclin D1 and Ki-67. No significant differences in Wnt3a, nuclear β-catenin, Cyclin D1 and Ki-67 expression were observed between dysplastic NHOL and HOL.
conclusionsWe conclude that, in clear contrast to non-dysplastic HOL, Wnt/β-catenin activity is increased in non-dysplastic NHOL, which correlates with the expression of downstream proliferation markers. Additionally, both dysplastic NHOL and HOL present high Wnt/β-catenin activity, regardless of the dysplasia grade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.